FBC
ONCY

Fairfield, Bush & Co’s Oncolytics Biotech ONCY Stock Holding History

Fairfield, Bush & Co’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-705
Closed -$1K – 347
2022
Q2 		$1K Buy
+705
New +$857 ﹤0.01% 434

Other funds holding ONCY

IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

Fairfield, Bush & Co's ONCY Position: Q3 2022 in Review

Fairfield, Bush & Co sold out of Oncolytics Biotech (ONCY) in Q3 2022, closing a stake of 705 shares — an estimated $1K sold.

Fairfield, Bush & Co first reported a position in ONCY in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 36 funds tracked by Wall St. Rank hold ONCY as of Q3 2022.

  • Fairfield, Bush & Co reported no remaining Oncolytics Biotech position as of Q3 2022 after selling out during the quarter.
  • Fairfield, Bush & Co sold 705 Oncolytics Biotech shares in Q3 2022, an estimated $1K.
  • Fairfield, Bush & Co first reported a position in Oncolytics Biotech in Q2 2022 and held it in 1 quarter.
  • Fairfield, Bush & Co's Oncolytics Biotech position peaked at $1K in Q2 2022.
  • 36 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q3 2022.

Based on Fairfield, Bush & Co's 13F filing for Q3 2022, filed 7 Nov 2022.